|Bid||39.82 x 800|
|Ask||40.06 x 900|
|Day's range||39.63 - 40.27|
|52-week range||30.10 - 49.07|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||60.90|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Hello, and welcome to the Genmab conference call to discuss the Company's financial results for the first half of 2021.
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.